STOCK TITAN

Zentalis Pharmaceuticals Inc - ZNTL STOCK NEWS

Welcome to our dedicated news page for Zentalis Pharmaceuticals (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zentalis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zentalis Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.93%
Tags
earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.51%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
conferences
Zentalis Pharmaceuticals Inc

Nasdaq:ZNTL

ZNTL Rankings

ZNTL Stock Data

1.12B
50.39M
4.22%
114.89%
23.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ZNTL

developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer